These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Ongoing||2005-001212-44||Letrozole adjuvant therapy duration (LEAD)study: standard versus long treatment. A phase III study in postmenopausal women with early breast cancer||not-yet-due|
|Ongoing||2005-001213-18||Letrozole adjuvant therapy after tamoxifen. Study of gene CYP19 correlation with letrozole efficacy in postmenopausal early breast cancer patients||not-yet-due|
|Completed, but no date||2005-005548-21||Phase I-II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Erlotinib (EGFR TKI) plus Oxaliplatin and Capecitabine (XELOX) in Patients with Metastatic Colorectal Cancer: XELOX-TARAV study||bad-data|
|Completed, but no date||2007-005977-67||SUNITINIB EITHER BEFORE OR AFTER CYTOREDUCTIVE NEPHRECTOMY A PHASE II TRIAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA||bad-data|
|Ongoing||2007-006031-30||A Randomized Trial with factorial Design comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in metastatic breast cancer progressing after Aromatase Inhibitor therapy||not-yet-due|
|Ongoing||2008-000486-29||A feasibility study of dose-dense FEC wiith G-CSF support followed by dose-dense Ixabepilone wiith G-CSF support as neoadjuvant chemotherapy in ER- negative breast cancer||not-yet-due|
|Ongoing||2008-006798-33||Medical optimization of TORisel (MoTOR): MULTICENTER, PHASE II EVALUATION OF TORISEL AS II-LINE TREATMENT FOR METASTATIC RCC PATIENTS PROGRESSING AFTER CYTOKINE THERAPY, TYROSINE KINASE, OR ANGIOGENES...||not-yet-due|
|Ongoing||2013-003194-10||A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Bre...||not-yet-due|
|Ongoing||2013-005044-29||A randomised, multicentre, open-label Phase II trial investigating activity of chemotherapy and lapatinib and Trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) refractory to an...||not-yet-due|
|Ongoing||2014-003798-41||Randomized phase III study of fulvestrant as maintenance therapy after first-line chemotherapy in HER2 negative postmenopausal metastatic breast cancer patients||not-yet-due|
|Ongoing||2014-004035-38||Fulvestrant ed EVerolimus più EXemestane nel carcinoma mammario metastatico” “Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopausal ...||not-yet-due|
|Ongoing||2015-000194-12||Isoquercetin as an adjunct therapy in patients with kidney cancer receiving first-line sunitinib: a phase I/II trial||not-yet-due|